iGlarLixi CGM Study in Chinese T2D Individuals After OADs
Sanofi · Type 2 Diabetes (T2D)
Phase 4
Recruiting
678
2026-03
Industry sponsor intelligence
SanofiClinical Pipeline.
Lead-sponsor view of Sanofi's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 53
- Recruiting
- 1
- Active
- 0
- Completed
- 46
- Results posted
- 29
- Avg enrollment
- 868
Pipeline overview
Programs by phase and activity.
Velocity
Sanofi trials by start year
Study start year · indexed snapshot
Development
Trials by phase
53phase labels
Early Phase 10
Phase 15
Phase 27
Phase 336
Phase 45
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Lixisenatide → | 46 | 5 | 5 | 31 | 5 | 1 |
| Efpeglenatide → | 4 | 0 | 0 | 4 | 0 | 0 |
| Eptifibatide → | 2 | 0 | 1 | 1 | 0 | 0 |
| Albiglutide → | 1 | 0 | 0 | 1 | 0 | 0 |
| Icatibant → | 1 | 0 | 1 | 0 | 0 | 0 |
Active peptide trials
In motion now.
NCT IDStudyPhase / statusEnrollmentUpdated
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus
Sanofi · Type 2 Diabetes
Phase 4
Completed
105
2026-07
iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)
Sanofi · Type 2 Diabetes Mellitus
Phase 3
Completed
582
2025-09
Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus
Sanofi · Type 2 Diabetes Mellitus
Phase 4
Completed
124
2025-09
Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)
Sanofi · Type 2 Diabetes Mellitus
Phase 3
Completed
878
2022-07
Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin
Sanofi · Type 2 Diabetes Mellitus
Phase 3
Completed
426
2022-07
A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)
Sanofi · Type 2 Diabetes Mellitus
Phase 1
Completed
23
2022-04
Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan
Sanofi · Diabetes Mellitus, Type 2
Phase 4
Completed
184
2022-04
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)
Sanofi · Type 2 Diabetes Mellitus
Phase 3
Completed
247
2022-04
Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM)
Sanofi · Type 2 Diabetes Mellitus
Phase 3
Completed
265
2022-04
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
Sanofi · Type 2 Diabetes Mellitus
Phase 3
Completed
514
2022-03
Showing 10 of 46 studies
Search sponsor records
All Sanofi studies.
This page groups studies where Sanofi is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
53 matching studies
Last registry update first
Recent updates
Latest registry movement.
NCT06716424A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes MellitusJul 10, 2026NCT06671587iGlarLixi CGM Study in Chinese T2D Individuals After OADsMar 17, 2026NCT05413369iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)Sep 24, 2025NCT05114590Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes MellitusSep 9, 2025NCT03798054Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)Jul 19, 2022NCT03798080Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal InsulinJul 19, 2022NCT02803918A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)Apr 25, 2022NCT02941367Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During RamadanApr 25, 2022NCT03529123Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)Apr 25, 2022NCT03767543Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM)Apr 25, 2022